|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1954-10-11 |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis in Patients With Head & Neck Cancer
This study is looking at a new medication called NG11-2 to see if it can reduce a side effect called severe Radiation-induced Oral Mucositis (RIOM) that can happen to people getting radiation treatment for head and neck cancer. Severe RIOM can make patients very sick and make it hard for them to finish their cancer treatment. Right now, there are no approved drugs that can prevent or treat severe RIOM. This study will test different doses of NG11-2 to find the best one, and then more patients will take that dose to see if it works. This study is being done at multiple hospitals in the UK.
A phase-1b dose escalation study to assess the effect of NG11-2 on radiation induced oral mucositis in patients with head & neck cancer
100 项与 Vasodynamics Ltd. 相关的临床结果
0 项与 Vasodynamics Ltd. 相关的专利(医药)
100 项与 Vasodynamics Ltd. 相关的药物交易
100 项与 Vasodynamics Ltd. 相关的转化医学